Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 3/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 4/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987549 | 1.00 | DPP7 (0.52) | DPP7ESR1ESR2NAMPTTAS1R3 | |
| SCHEMBL114156 | 0.89 | ESR1 (0.65) | DPP7ESR1ESR2HPGDABHD6 | |
| SCHEMBL29805828 | 0.89 | ESR1 (0.65) | DPP7ESR1ESR2HPGDABHD6 | |
| SCHEMBL3359328 | 0.87 | ESR1 (0.55) | DPP7ESR1ESR2PNMTADRA2A | |
| SCHEMBL14348619 | 0.83 | DPP7 (0.43) | DPP7ESR1ESR2NAMPTTAS1R3 | |
| SCHEMBL30962669 | 0.83 | DPP7 (0.43) | DPP7ESR1ESR2NAMPTTAS1R3 | |
| SCHEMBL720157 | 0.83 | ESR1 (0.53) | ESR1ESR2PNMTADRA2AHPGD | |
| SCHEMBL23327780 | 0.82 | ESR1 (0.41) | DPP7ESR1ESR2NAMPTTAS1R3 | |
| SCHEMBL2060884 | 0.82 | TDP2 (0.40) | DPP7ESR1ESR2TAS1R3TAS1R1 | |
| SCHEMBL1393124 | 0.81 | DPP7 (0.56) | DPP7NAMPTTAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-11-28 | — | — | US | disclosed |
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-11-28 | — | — | US | disclosed |
| US-20220411418-A1 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-12-29 | — | — | US | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
| WO-2018208132-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-11-15 | — | — | WO | disclosed |
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-06-09 | — | — | US | disclosed |
| WO-2016090079-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090079-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-8633173-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501936-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2438066-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES | Cephalon, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141796-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES | CEPHALON, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | HSP90AA1, HSP90AB1, HSP90AB2P | DPP7 2740/4885ESR1 1829/4885ESR2 856/4885 |
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | JAK2, JAK1, JAK3 | DPP7 4051/4885ESR1 1103/4885ESR2 822/4885 |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | BTK, SYK, LCK | DPP7 967/4885ESR1 4753/4885ESR2 4806/4885 |
| US-20220411418-A1 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | CISD2, CISD1, FECH | DPP7 4414/4885ESR1 3918/4885ESR2 902/4885 |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CCNA1, CCNY, RB1 | DPP7 4688/4885ESR1 962/4885ESR2 966/4885 |
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | DPP7 98/4885ESR1 3303/4885ESR2 2068/4885 |
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | CISD2, CISD1, FECH | DPP7 4414/4885ESR1 3918/4885ESR2 902/4885 |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | BTK, SYK, LCK | DPP7 967/4885ESR1 4753/4885ESR2 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.